EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube

News archive

Recent news

  • Job Title: Medical and Scientific Officer
  • Position Type: Full time/permanent 
  • Probation period: 6 months
  • Travel Required:  15 days/year (approx.) 
  • Location: European Union (preferably Germany, Belgium or Spain) or United Kingdom/home-based
  • Gross salary: 40.000 EUR/year

Continue reading

  • Job Title: Chief Executive Officer
  • Position Type: Full time/permanent 
  • Probation period: 6 months
  • Travel Required:  30 days / year (approx.) 
  • Location: Europe (preferably Germany, Spain, Belgium or UK)

Continue reading

 

Myeloma Patients Europe (MPE) has today relaunched the Myeloma Access Atlas, an online platform designed to provide myeloma and AL amyloidosis patient advocates with the information and tools needed to work effectively on access issues. Explore the Platform here.

 

The Atlas provides country-specific and comparative information on European healthcare systems, including data on system performance and on access inequalities to myeloma treatments. The aim behind the data and tools provided is to identify, understand and overcome variation in access to treatment and care in Europe. It is also underpinned by the policy and regulatory work MPE does in Europe.

Continue reading

 

Last March, a number of hematology patient associations, including Myeloma Patients Europe (MPE), coordinated by the Acute Leukemia Advocates Network, wrote a letter to the American Society of Hematology (ASH) that patient advocates need free access to the ASH Annual meeting. The message was heard and non-profit patient advocates (employees and volunteers) from registered patient organisations can now apply to attend the 63rd ASH Annual Meeting in December.
Continue reading

    

CAR-T is a form of immunotherapy recently approved for the treatment of myeloma in the United States and Europe. While the process of manufacturing and administrating this treatment as well as side effects can be challenging, results of clinical trials have been promising in myeloma. Continue reading

 

The European Commission (EC) has granted marketing authorisation for the expanded use of daratumumab (Darzalex®) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. Continue reading

1 2 3 27